74 results about "Pro-apoptosis" patented technology

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

The present invention provides phosphaplatins, stable isolated monomeric phosphate complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes-unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents-do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.

The present invention generally relates to viral vectors and their use as expression vectors for transforming human cells, both in vitro and in vivo. More particularly, the present invention relates to adenoviral vectors containing propapoptotic genes and their use in cancer therapy.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1/DR4 and TRAIL-R2/DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1/DR4 and/or TRAIL-R2/DR5 agonists.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1/DR4 and TRAIL-R2/DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1/DR4 and/or TRAIL-R2/DR5 agonists.

The invention discloses a pyrazolo[3,4-d]pyrimidine derivative that is represented as the formula (I), which has significant growth inhibiting effect, apoptosis promoting effect and cell proliferation alleviating effect on tumor cells, can be used for preventing and/or treating tumor related diseases, and has wide application prospect.

The invention discloses application of a pentacyclic triterpene compound and a medicine composition, and further discloses the pentacyclic triterpene compound shown in the formula A or the formula B in the specification, and application of a stereoisomer or a tautomer or pharmaceutically acceptable salt or solvate or polymorph of the pentacyclic triterpene compound in preparing medicine for treating diseases (especially cancer) caused by cell apoptosis or cell damage and a BCL-XL inhibitor. R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are independently selected from one of hydroxyl, hydrogen, halogen, COR13, COOR14, C1-C4 alkoxy and C1-C4 alkyl, and R6, R12, R13 and R14 are independently selected from hydrogen or C1-C5 alkyl. The pentacyclic triterpene compound has higher inhibitory activity on binding between BCL-XL and pro-apoptosis protein and has guiding significance on design and research and development of the medicine.

The present invention provides methods and kits for predicting recurrence of tumor or cancer in a mammal by calculating the ratio of the amount of Survivin to the amount of pro-apoptosis factor (PAF) in a physiological sample.

The invention discloses a drug-loading nano-liposome, and a preparation method and application thereof. The invention relates to the field of synthesis and treatment of nano-liposomes, in particular to a nano-liposome co-loading PEG-C16-ceramide and adriamycin, the preparation method of the nano-liposome, and the application of the nano-liposome to the field of tumor treatment. The nano-liposome (Lipo-ADR-Cer) co-loading the PEG-C16-ceramide and the adriamycin is constructed, the preparation method and the stability of the Lipo-ADR-Cer are disclosed, and the basic representation, the in-vitro release process and the in-vitro cell transfection endocytosis efficiency of the liposome are not changed. In terms of tumor drug-resistant cell strains, the in-vitro cytotoxicity, the in-vitro apoptosis-promoting ability and the in-vivo treatment effect of the Lipo-ADR-Cer are improved. The PEG-C16-ceramide and the adriamycin can be co-loaded, the adriamycin IC50 of the drug-resistant cells can be reduced, and the nano-liposome can be used for treating drug-resistant tumor cells.

Disclosed herein are nucleic acid sequences that encode pro-apoptotic polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of proliferative disorders and bacterial infections using the nucleic acids and proteins of the invention.

The present invention features a novel method of treating vascular disease that involves modifying smooth muscle cells to express a gene encoding a protein having both anti-inflammatory and pro-apoptotic activity. Preferably, the protein of the invention also has an anti-proliferative effect in smooth muscle cells. In general, the method is useful in preparing vascularized organs and vessels for transplant into a patient. Alternatively, the present invention can be applied to treat atherosclerotic lesions in damaged vessels.

The invention relates to a cell-penetrating peptide, optionally linked to a pro-apoptotic peptide, useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors.

The invention discloses a novel molecular target DUSP21 for promoting apoptosis of imatinib-resistant chronic myeloid leukemia cells (K562/G01), and correspondingly provides shRNA (short hairpin ribonucleic acid) for inhibiting target molecules and application of the shRNA. The shRNA is psc60342 or psc60343, is a targeted DUSP21 gene and interferes with the expression of DUSP21, can inhibit the expression of DUSP21 in K562/G01 and promote the apoptosis of K562/G01 cells, can be applied to preparation of drugs for inhibiting the proliferation of human imatinib-resistant chronic myeloid leukemia cells and promoting the apoptosis, and a new way is provided for the development of new drugs for treating imatinib-resistant chronic myeloid leukemia.

The invention relates to an application of miR-491 in preparing medicines for treating osteosarcoma. According to the application, miR-491 is used for preparing medicines for inhibiting osteosarcoma growth, pulmonary metastasis and pulmonary metastatic relapse. MiR-491 and a pharmaceutically acceptable carrier are bonded, and the bonded MiR-491 and pharmaceutically acceptable carrier are compounded with antitumor drugs and/or pharmaceutically acceptable auxiliary materials to prepare the medicinal composition. For the medicinal composition, miR-491 is adopted as the active ingredient, whereinthe nucleotide sequence of miR-491 is shown as SEQ ID No.1. The medicinal composition contains miR-491 bonded to the carrier and/or the pharmaceutically acceptable auxiliary materials. The in-vivo andin-vitro experiments prove that after overexpression of miR-491, the growth of osteosarcoma and pulmonary metastasis can be effectively inhibited, the inhibiting effect and apoptosis-promoting effectof cis-platinum for osteosarcoma cells can be promoted, which means that miR-491 enhances the anticancer effect of platinum-containing medicines, and can be used for preparing novel treatment medicines for treating osteosarcoma cell pulmonary metastasis, and thus possibility is provided for clinical treatment of pulmonary metastatic osteosarcoma.